View in EDS

328PRibociclib (RIBO) + letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial

Saved in:
Bibliographic Details
Title: 328PRibociclib (RIBO) + letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial
Authors: Abdel-Razeq, H1 (AUTHOR), Cottu, P H2 (AUTHOR), Ring, A3 (AUTHOR), Laurentiis, M De4 (AUTHOR), Lu, J5 (AUTHOR), Azim, H A6 (AUTHOR), Zamagni, C7 (AUTHOR), Zhou, K8 (AUTHOR), Wu, J8 (AUTHOR), Menon, L8 (AUTHOR)
Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdy272.318